TCT Late Breaking Clinical Session is about to be released:
Chinese original world's smallest VAD "NyokAssist®" clinical achievement, impacting the new global standard for high-risk PCI treatment
From October 25th to 29th, the world's most influential cardiovascular intervention conference, TCT 2025, will be held grandly at the Moscone Center in San Francisco, USA.
Xinqing Medical will collaborate with the team of Academician Ge Junbo from Zhongshan Hospital affiliated with Fudan University, Academician Wang Jian'an from the Second Affiliated Hospital of Zhejiang University School of Medicine, and multi center clinical research experts to launch the world's smallest and foldable ventricular assist device, NyokAssist®, for the first time at the global authoritative Late Breaking Clinical Science event; Clinical research results in high-risk coronary intervention (HR-PCI) treatment.
Late-Breaking
Special session NyokAssist®
Global first multicenter randomized controlled clinical trial results
This release focuses on "SAVE-PCI"
A prospective randomized controlled clinical trial comparing the supportive effects of small diameter percutaneous ventricular assist device (pVAD) and intra aortic balloon counterpulsation (IABP) in high-risk PCI patients
This study was jointly conducted by academician Ge Junbo from Zhongshan Hospital affiliated with Fudan University and clinical teams from several well-known centers in China. It systematically evaluated the application value of a new interventional ventricular assist device for the most challenging high-risk PCI scenario in current clinical practice.
This is the first prospective large-scale randomized controlled study globally to systematically evaluate small-sized, foldable VAD and IABP support strategies, and it is also the first time that China's original pVAD technology has been selected for the TCT Late Breaking Clinical Science session.
Three TCT keywords
Define this milestone release
• Pioneering Research—— Chinese original works enter the global core clinical research stage
• Groundbreaking Discovery—— Prospective clinical evidence of head to head comparison between small-sized VAD and IABP for the first time
• Unmatched Impact—— Attracting widespread attention from top international clinical experts
TCT selects a very small number of studies from global submissions each year to enter the Late Breaking Clinical Science session, representing the highest academic recognition and international dissemination value. NyokAssist® As one of the few projects selected by China's independently developed equipment to date, it has important international academic and industrial significance.
The smallest challenge is to overcome the hardest
NyokAssist® Synchronized release of practical clinical cases
NyokAssist® The structural breakthrough was achieved with a maximum outer diameter of 9Fr, but faced the most complex and high-risk clinical scenarios.
In addition to complete randomized controlled trial data, the research team will also present prospective animal experiments and multiple real-world Challenging Cases at the TCT site.
This will not only be a showcase of product capabilities, but also a systematic response to the most difficult treatment challenges.
Special invitation
Xinqing Medical Booth 2330 · Discussing the Future Together
During TCT 2025, ASRock Medical will showcase NyokAssist® at booth 2330; We cordially invite experts, partners, and peers in the global cardiovascular field to visit and exchange ideas on our technology platform and research achievements.
On site, there will also be device displays, case explanations, and face-to-face interactions with research teams to deeply interpret clinical usage experience and technical details.
Not just an international appearance
Still the beginning of the journey towards globalization
NyokAssist® We are responding to global treatment challenges with rigorous clinical data and promoting the establishment of a genuine and credible voice for Chinese original medical technology in the international academic system.
We will not only bring original data from China, but also soon launch formal clinical trials in the United States, moving towards a global multi center research phase. We look forward to meeting you at TCT 2025, witnessing the new solutions brought by Chinese innovation to high-risk PCI treatment worldwide, and exploring the future direction of mechanical circulation support together.
The schedule overview is as follows
